Aurora, CO Clinical Trials Report — June 2026

For patients and healthy volunteers in Aurora, CO, June 2026 presents a mix of urgent opportunities and significant new research avenues. Across the city, 56 clinical trials are scheduled to conclude within the next 90 days, making prompt action essential for those interested in participating.

Among these rapidly closing studies, 7 trials are still actively seeking healthy volunteers, offering a chance to contribute to medical advancements before their enrollment windows close. This provides a valuable opportunity for individuals without specific health conditions to support research efforts.

Impending Deadlines for Specific Conditions

Patients managing particular health conditions also face limited time to join research. Trials focused on various conditions are among those with impending deadlines for enrollment:

• Transgenderism (2 trials)
• Duchenne muscular dystrophy (2 trials)
• Lupus nephritis (2 trials)
• B-cell acute lymphoblastic leukemia (2 trials)
• Head and neck squamous cell carcinoma (2 trials)
• Advanced solid tumor (1 trial)
• Advanced breast cancer (1 trial)
• Acute liver failure (1 trial)
• Artificial intelligence (1 trial)
• Anger (1 trial)

New Research Opportunities in Aurora

This month, Aurora saw the opening of 14 new clinical trials. This figure is lower than the 21 trials that launched in May 2026, but it still adds to the city's robust research landscape. Currently, 976 clinical trials are actively recruiting participants across 303 research facilities in Aurora, CO.

June brings several notable new trials to Aurora, including Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• AstraZeneca is sponsoring NCT07664553, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin." This Phase 3 study aims for 600 participants to evaluate the efficacy, safety, and tolerability of elecoglipron in adults with Type 2 Diabetes Mellitus treated with background insulin and other glucose-lowering medications.
• Also from AstraZeneca, NCT07652658 is "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF." This Phase 2b study will assess the efficacy, safety, and tolerability of AZD8965 at 3 different doses compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF).
• NYU Langone Health is sponsoring NCT07656584, "Implementation of Communication Disability Collection and Accommodations in Primary Care Settings." This multi-methods-multi-site study aims to adapt and evaluate strategies to help primary care clinics document patients' communication disability and accommodation needs in electronic health records.
• RTI International is leading NCT07625579, "Collaboration for Down Syndrome Progress (CDP)." This long-term observational study follows people with Down syndrome of all ages to better understand their health, development, and everyday experiences over time.
• The University of Colorado, Denver is sponsoring NCT07634627, "UNderstanding the Causes Of Idiopathic Scoliosis Through the Longitudinal Analysis of Proteomic Markers: the UNCOIL Study." This observational study seeks to find clinical, demographic, and protein biomarkers related to scoliosis progression.
• Bayer is sponsoring NCT07625215, "A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation." This Phase 2 study will compare BAY 3670549 to a placebo in people with atrial fibrillation.

New trials this month are exploring a range of conditions. Conditions with new trials include adolescent idiopathic scoliosis, advanced solid tumor cancer, atrial fibrillation, brain cancer, chromosome disorders, circadian misalignment, communication disabilities, Down syndrome, glioblastoma, and studies for healthy individuals. Drug trials account for the largest share of new studies, with 5 new drug trials, followed by 4 behavioral studies and 4 other types of studies.

Academic institutions are significant drivers of new research in Aurora. The University of Colorado, Denver is sponsoring 4 of the new trials, while AstraZeneca is sponsoring 2. Other notable sponsors include NYU Langone Health and RTI International.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are opportunities to contribute to research. Of the 14 new trials launched this month, 1 is actively seeking healthy volunteers. Across Aurora, a total of 118 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Aurora's Leading Research Facilities

Aurora is home to some of Colorado's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Children's Hospital Colorado (159 trials)
• University of Colorado Anschutz Medical Campus (95 trials)
• University of Colorado (79 trials)
• UCHealth University of Colorado Hospital (53 trials)
• University of Colorado Hospital (49 trials)
• University of Colorado Cancer Center (38 trials)
• University of Colorado Denver (27 trials)
• Rocky Mountain Regional VA Medical Center, Aurora, CO (25 trials)
• Research Site (25 trials)
• Rocky Mountain Cancer Centers-Aurora (24 trials)

These institutions offer a broad spectrum of research, from pediatric care at Children's Hospital Colorado, to comprehensive medical and cancer research across the University of Colorado Anschutz Medical Campus and its affiliated hospitals, and specialized care at the Rocky Mountain Regional VA Medical Center.

Broadening Your Search: Nearby Options

While Aurora offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Colorado. Cities with active trials include Boulder (6 trials), Denver (5 trials), Fort Collins (4 trials), Colorado Springs (3 trials), Centennial (2 trials), Steamboat Springs (1 trial), Englewood (1 trial), and Lakewood (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 14 new trials launched this month, 10 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials include children, and 1 is female-only.

As we move through June, Aurora's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.